Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial

8,397 patients with stable coronary disease from the EUROPA trial, mean age 60, 87% male. Key inclusion: objective evidence of coronary disease (prior MI, CABG, PCI, or angiographic stenosis >70%) without clinical heart failure.

Presence of metabolic syndrome (defined by modified NCEP criteria)

Absence of metabolic syndrome

Composite of cardiovascular death, myocardial infarction, or resuscitated cardiac arrest at mean 4.2 years follow-upcomposite